[MR Detection of Local Prostate Cancer Recurrence After Transrectal High-intensity Focused US Treatment: Preliminary Results]
Authors
Affiliations
Purpose: To assess T2W and dynamic: contrast-enhanced (DCE) MR imaging in the detection of local tumor recurrence after transrectal high-intensity focused US (HIFU) treatment.
Materials And Methods: Fifteen patients treated by HIFU for prostate cancer were referred for MR due to biological evidence of tumor recurrence. Axial, sagittal and coronal T2W images and DCE images (12 3-mm thick axial images, temporal resolution: 15 seconds) were obtained first. Transrectal biopsies were then obtained under US guidance. MR findings were compared to biopsy results for 10 prostate sectors.
Results: Biopsies demonstrated tumor recurrence in 13/15 patients (23/108 sectors). On T2W images, the treated prostate tissue was diffusely hypointense which interfered with interpretation. Three patients (5 sectors) had suspicious areas of T2W signal abnormality and 15 patients (29 sectors) had suspicious areas on DCE scans. An analysis per sector for T2W and DCE imaging showed sensitivity, specificity, positive predictive and negative predictive values respectively of 0.13, 0.98, 0.6 and 0.81 and 0.70, 0.85, 0.55 and 0.91. DCE MR was strongly predictive of positive biopsy results (Odds ratio: 12.8 (95% confidence interval: 4.4-37.3)) whereas T2W imaging was not (Odds ratio: 4.0 (95% confidence interval: 0.5-30)).
Conclusion: MR, especially DCE MR, is promising for the detection and localization of local prostate cancer recurrence after transrectal HIFU treatment.
The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer.
Pio F, Murdock A, Fuller R, Whalen M Cancers (Basel). 2024; 16(18).
PMID: 39335196 PMC: 11430134. DOI: 10.3390/cancers16183225.
Ahn H, Hwang S, Kim T, Lee H, Choe G, Hong S Prostate Cancer Prostatic Dis. 2022; 26(2):360-366.
PMID: 35643729 DOI: 10.1038/s41391-022-00531-8.
Shah T, Peters M, Kanthabalan A, McCartan N, Fatola Y, van der Voort van Zyp J Prostate Cancer Prostatic Dis. 2016; 19(3):311-6.
PMID: 27431499 PMC: 4983180. DOI: 10.1038/pcan.2016.23.
Lee D, Ahmed H, Moore C, Emberton M, Ehdaie B Curr Urol Rep. 2014; 15(3):390.
PMID: 24430171 DOI: 10.1007/s11934-013-0390-1.
Ultrasonic enhancement of drug penetration in solid tumors.
Lai C, Fite B, Ferrara K Front Oncol. 2013; 3:204.
PMID: 23967400 PMC: 3746679. DOI: 10.3389/fonc.2013.00204.